Free Trial

Oramed Pharmaceuticals (ORMP) Competitors

Oramed Pharmaceuticals logo
$2.16 +0.06 (+2.86%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$2.20 +0.04 (+1.81%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORMP vs. TERN, ARCT, CMPX, ATXS, SNDL, GOSS, MBX, AQST, CYRX, and IVA

Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Terns Pharmaceuticals (TERN), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), Astria Therapeutics (ATXS), SNDL (SNDL), Gossamer Bio (GOSS), MBX Biosciences (MBX), Aquestive Therapeutics (AQST), CryoPort (CYRX), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.

Oramed Pharmaceuticals vs. Its Competitors

Terns Pharmaceuticals (NASDAQ:TERN) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.34 beat Oramed Pharmaceuticals' score of 0.39 indicating that Terns Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Terns Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oramed Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Oramed Pharmaceuticals' return on equity of -11.34% beat Terns Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Terns PharmaceuticalsN/A -28.81% -27.55%
Oramed Pharmaceuticals N/A -11.34%-10.73%

Terns Pharmaceuticals currently has a consensus target price of $15.63, suggesting a potential upside of 266.78%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Oramed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Terns Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60
Oramed Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Oramed Pharmaceuticals has higher revenue and earnings than Terns Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Terns Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Terns PharmaceuticalsN/AN/A-$88.85M-$1.09-3.91
Oramed Pharmaceuticals$1.34M65.85-$19.06M-$0.44-4.91

Terns Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.

98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 1.5% of Terns Pharmaceuticals shares are held by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Oramed Pharmaceuticals beats Terns Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORMP vs. The Competition

MetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$85.79M$10.49B$5.54B$8.87B
Dividend YieldN/A2.09%5.39%4.10%
P/E Ratio-4.9116.6626.1919.90
Price / Sales65.8529.93414.04113.66
Price / CashN/A22.7836.1356.90
Price / Book0.603.648.025.38
Net Income-$19.06M$233.36M$3.15B$248.50M
7 Day Performance-0.46%1.00%1.48%2.06%
1 Month Performance-4.42%3.01%3.67%4.86%
1 Year Performance-14.96%-11.64%34.68%20.24%

Oramed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORMP
Oramed Pharmaceuticals
0.5678 of 5 stars
$2.16
+2.9%
N/A-16.1%$85.79M$1.34M-4.9110News Coverage
TERN
Terns Pharmaceuticals
4.0978 of 5 stars
$3.68
-5.6%
$15.63
+324.6%
-36.6%$340.61MN/A-3.3840
ARCT
Arcturus Therapeutics
3.7715 of 5 stars
$12.51
+1.8%
$53.50
+327.7%
-36.6%$333.31M$152.31M-4.94180News Coverage
Positive News
Analyst Forecast
CMPX
Compass Therapeutics
3.0594 of 5 stars
$2.54
+5.8%
$13.13
+416.7%
+197.7%$331.88M$850K-6.2020News Coverage
Analyst Upgrade
ATXS
Astria Therapeutics
1.8469 of 5 stars
$5.61
-4.3%
$30.00
+434.8%
-36.1%$330.70MN/A-3.0030News Coverage
SNDL
SNDL
3.9501 of 5 stars
$1.24
-0.8%
$3.63
+192.3%
-33.5%$328.47M$671.81M-4.282,516Positive News
GOSS
Gossamer Bio
3.6963 of 5 stars
$1.37
-4.9%
$7.75
+465.7%
+26.1%$327.32M$114.70M-5.96180
MBX
MBX Biosciences
2.3265 of 5 stars
$9.73
-0.1%
$37.50
+285.4%
N/A$325.22MN/A0.0036
AQST
Aquestive Therapeutics
1.4074 of 5 stars
$3.29
+1.2%
$10.14
+208.3%
+52.1%$322.82M$57.56M-5.58160News Coverage
CYRX
CryoPort
2.0847 of 5 stars
$6.56
+3.0%
$11.00
+67.7%
+20.4%$319.37M$228.38M-2.801,186Gap Down
IVA
Inventiva
3.4853 of 5 stars
$3.34
+1.5%
$10.40
+211.5%
+4.6%$314.73M$9.95M0.00100Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:ORMP) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners